[go: up one dir, main page]

BR9708772A - "comprimidos famacêuticos de liberação controlada que contém um veìculo à base de amilose reticulada e hidróxi propil metil celulose" - Google Patents

"comprimidos famacêuticos de liberação controlada que contém um veìculo à base de amilose reticulada e hidróxi propil metil celulose"

Info

Publication number
BR9708772A
BR9708772A BR9708772-6A BR9708772A BR9708772A BR 9708772 A BR9708772 A BR 9708772A BR 9708772 A BR9708772 A BR 9708772A BR 9708772 A BR9708772 A BR 9708772A
Authority
BR
Brazil
Prior art keywords
cross
linked amylose
controlled
methyl cellulose
vehicle based
Prior art date
Application number
BR9708772-6A
Other languages
English (en)
Inventor
Francois Chouinard
Original Assignee
Labopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labopharm Inc filed Critical Labopharm Inc
Publication of BR9708772A publication Critical patent/BR9708772A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<B>COMPRIMIDOS FARMACêUTICOS DE LIBERAçãO CONTROLADA QUE CONTêM UM VEìCULO à BASE DE AMILOSE RETICULADA E HIDRóXI PROPIL METIL CELULOSE<D>, ou seja, um comprimido farmacêutico de liberação controlada que contém um ingrediente ativo em combinação com um veículo formado por amilose reticulada no qual hidróxi propil metil celulose (HPMC) com uma viscosidade igual ou maior do que 4.000 cps é adicionada como adjuvante. A adição da HPMC ao comprimido permite controlar o efeito das enzimas, e mais particularmente da alfa-amilase, presentes no meio intestinal, sobre a amilose reticulada usada como veículo e, desse modo, reduzir a dependência da cinética de liberação na concentração de enzimas presentes no meio.
BR9708772-6A 1996-04-10 1997-04-04 "comprimidos famacêuticos de liberação controlada que contém um veìculo à base de amilose reticulada e hidróxi propil metil celulose" BR9708772A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002173818A CA2173818A1 (fr) 1996-04-10 1996-04-10 Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
PCT/CA1997/000229 WO1997037639A1 (fr) 1996-04-10 1997-04-04 Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose

Publications (1)

Publication Number Publication Date
BR9708772A true BR9708772A (pt) 2000-01-04

Family

ID=4157953

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9708772-6A BR9708772A (pt) 1996-04-10 1997-04-04 "comprimidos famacêuticos de liberação controlada que contém um veìculo à base de amilose reticulada e hidróxi propil metil celulose"

Country Status (22)

Country Link
US (1) US5885615A (pt)
EP (1) EP0954290B1 (pt)
JP (1) JP4166278B2 (pt)
KR (1) KR100439614B1 (pt)
CN (1) CN1218396A (pt)
AT (1) ATE240719T1 (pt)
AU (1) AU711089B2 (pt)
BR (1) BR9708772A (pt)
CA (1) CA2173818A1 (pt)
CZ (1) CZ294342B6 (pt)
DE (1) DE69722247T2 (pt)
DK (1) DK0954290T3 (pt)
ES (1) ES2200166T3 (pt)
IL (1) IL126477A (pt)
MY (1) MY115535A (pt)
NO (1) NO321862B1 (pt)
NZ (1) NZ332576A (pt)
PL (1) PL187764B1 (pt)
PT (1) PT954290E (pt)
TR (1) TR199802034T2 (pt)
WO (1) WO1997037639A1 (pt)
ZA (1) ZA973054B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119660A (en) 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
US6284273B1 (en) * 1998-02-24 2001-09-04 Vincent Lenaerts Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds
WO2000033818A1 (en) 1998-12-11 2000-06-15 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
EP1174127A1 (en) * 2000-07-21 2002-01-23 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Composition for targeted release of an actvie substance and process for producing such a composition
US6673369B2 (en) * 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
JP2005526079A (ja) * 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
AU2003275854B9 (en) * 2002-10-25 2009-08-27 Paladin Labs (Barbados) Inc. Controlled-release compositions
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
MY142195A (en) * 2002-10-25 2010-10-15 Labopharm Inc Controlled-release compositions
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
AU2003295963B2 (en) * 2002-11-25 2009-09-03 Boston Scientific Limited Injection device for treating mammalian body
MXPA05008033A (es) * 2003-01-28 2006-04-28 Collegium Pharmaceutical Inc Composiciones de milnacipran en forma de multiparticulas para administracion oral.
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
DK1940467T3 (da) * 2005-09-09 2017-02-13 Paladin Labs Inc Lægemiddelsammensætning med langvarig frigivelse
SI1931346T1 (sl) * 2005-09-09 2012-10-30 Angelini Labopharm Llc Trazodonski sestavek za dajanje enkrat dnevno
ATE540705T1 (de) * 2005-09-21 2012-01-15 Surmodics Inc Überzüge und artikel mit natürlichen biologisch abbaubaren polysacchariden
ATE454908T1 (de) * 2005-09-21 2010-01-15 Surmodics Inc In situ okklusionszusammensetzungen mit natürlichen biologisch abbaubaren polysacchariden
EP1946780B1 (en) * 2005-11-11 2012-01-11 Asahi Kasei Chemicals Corporation Controlled release solid preparation
US20080154241A1 (en) * 2006-12-07 2008-06-26 Burkstrand Michael J Latent stabilization of bioactive agents releasable from implantable medical articles
JP5763525B2 (ja) 2008-05-07 2015-08-12 サーモディクス，インコーポレイティド 粒子からの核酸複合体の送達
CA2735008C (en) * 2008-09-04 2016-11-29 Bristol-Myers Squibb Company Extended release formulation for optimized delivery of an hiv attachment inhibitor
CN107028908A (zh) * 2008-10-27 2017-08-11 阿尔扎公司 对乙酰氨基酚/曲马多口服延释剂型
US20100260842A1 (en) * 2009-04-06 2010-10-14 Rashmi Nair Pseudoephedrine pharmaceutical formulations
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4734285A (en) * 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
US4775535A (en) * 1986-04-04 1988-10-04 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
US4855143A (en) * 1986-04-04 1989-08-08 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
CA2041774C (en) * 1990-11-27 1994-04-19 Mircea A. Mateescu Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
US5603956A (en) * 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
NL9201196A (nl) * 1992-07-03 1994-02-01 Tno Preparaat voor de gereguleerde afgifte van een werkzame stof en werkwijze ter bereiding van een dergelijk preparaat.
DE69302580T2 (de) * 1992-07-24 1996-09-26 Labopharm Inc., Ste-Therese, Quebec Vernetztes polyhydroxyl-material zur enzymatisch gesteuerten arzneistofffreisetzung
US5616343A (en) * 1993-03-25 1997-04-01 Labopharm, Inc. Cross-linked amylose as a binder/disintegrant in tablets
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici

Also Published As

Publication number Publication date
TR199802034T2 (xx) 1999-02-22
NZ332576A (en) 2000-03-27
WO1997037639A1 (fr) 1997-10-16
DK0954290T3 (da) 2003-09-22
CZ325498A3 (cs) 1999-03-17
ZA973054B (en) 1998-06-01
ES2200166T3 (es) 2004-03-01
JP2000507561A (ja) 2000-06-20
CA2173818A1 (fr) 1997-10-11
KR100439614B1 (ko) 2004-10-14
DE69722247D1 (de) 2003-06-26
NO984703D0 (no) 1998-10-08
CZ294342B6 (cs) 2004-12-15
IL126477A0 (en) 1999-08-17
ATE240719T1 (de) 2003-06-15
PT954290E (pt) 2003-10-31
US5885615A (en) 1999-03-23
NO984703L (no) 1998-12-08
JP4166278B2 (ja) 2008-10-15
CN1218396A (zh) 1999-06-02
KR20000005337A (ko) 2000-01-25
DE69722247T2 (de) 2004-04-01
PL187764B1 (pl) 2004-10-29
AU2283297A (en) 1997-10-29
AU711089B2 (en) 1999-10-07
EP0954290B1 (fr) 2003-05-21
EP0954290A1 (fr) 1999-11-10
MY115535A (en) 2003-07-31
PL329285A1 (en) 1999-03-15
NO321862B1 (no) 2006-07-17
IL126477A (en) 2001-10-31

Similar Documents

Publication Publication Date Title
BR9708772A (pt) &#34;comprimidos famacêuticos de liberação controlada que contém um veìculo à base de amilose reticulada e hidróxi propil metil celulose&#34;
US5603956A (en) Cross-linked enzymatically controlled drug release
PT1028707E (pt) Formulacoes oftalmicas de libertacao controlada contendo medicamentos soluveis em agua
CA2321461A1 (en) Cross-linked high amylose starch having functional groups as a matrix for the slow release of pharmaceutical agents
ATE161174T1 (de) Feste zubereitung mit hoher freisetzung, ihre herstellung und verwendung
AR003928A1 (es) Comprimido del liberacion controlada
ES2184452T3 (es) Preparacion farmaceutica que contiene levotiroxina de sodio.
CA2140032C (en) Cross-linked amylose material for enzymatically controlled drug release
DE59706576D1 (de) Orale zubereitung, enthaltend in einer in wässrigem medium quellbaren matrix wenigstens einen pharmazeutischen wirkstoff
IT1250017B (it) Enzima immobilizzato, relativo procedimento di preparazione ed impiego
HUP9902681A2 (hu) Térhálósított amilózt és hidroxi-propil-metil-cellulózt tartalmazó hordozóval készült szabályozott felszabadulású tabletta gyógyszerkészítmény
IT1275267B (it) Forme farmaceutiche a rilascio modificato di canrenoato di potassio costituite da matrici idrofile rivestite

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/04/1997, OBSERVADAS AS CONDICOES LEGAIS.

B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 16A, 17A, 18A, 19A E 20A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2607 DE 22-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.